Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Fly Intel: Top five analyst initiations » 09:54
02/26/21
02/26
09:54
02/26/21
09:54
FATE

Fate Therapeutics

$39.00 /

+13 (+8.00%)

, CALT

Calliditas Therapeutics

$40.00 /

+13 (+8.00%)

, PSNL

Personalis

$34.00 /

+19 (+1.00%)

, MEDS

Trxade Group

$36.00 /

+16 (+1.00%)

, AMRS

Amyris

$33.00 /

+19 (+8.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Fate Therapeutics (FATE) initiated with a Buy at BofA. 2. Calliditas Therapeutics (CALT) initiated with a Buy at H.C. Wainwright. 3. Personalis (PSNL) assumed with a Buy at Needham. 4. Trxade Group (MEDS) initiated with a Buy at Maxim. 5. Amyris (AMRS) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
PSNL Personalis
$34.00 /

+19 (+1.00%)

MEDS Trxade Group
$36.00 /

+16 (+1.00%)

FATE Fate Therapeutics
$39.00 /

+13 (+8.00%)

CALT Calliditas Therapeutics
$40.00 /

+13 (+8.00%)

AMRS Amyris
$33.00 /

+19 (+8.00%)

FATE Fate Therapeutics
$39.00 /

+13 (+8.00%)

02/26/21
Fly Intel: Top five analyst downgrades
02/26/21
Fly Intel: Top five analyst downgrades
02/26/21 Truist
Fate Therapeutics price target raised to $135 from $85 at Truist
02/26/21 Truist
Fate Therapeutics price target raised to $135 from $85 at Truist
02/26/21 Wedbush
Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
02/26/21 Wedbush
Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
02/26/21 BofA
BofA starts Fate Therapeutics at Buy with $115 price target
02/26/21 BofA
BofA starts Fate Therapeutics at Buy with $115 price target
CALT Calliditas Therapeutics
$40.00 /

+13 (+8.00%)

02/26/21 H.C. Wainwright
Calliditas Therapeutics initiated with a Buy at H.C. Wainwright
02/26/21 H.C. Wainwright
Calliditas Therapeutics initiated with a Buy at H.C. Wainwright
07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
PSNL Personalis
$34.00 /

+19 (+1.00%)

02/26/21 Needham
Personalis assumed with a Buy at Needham
02/26/21 Needham
Personalis assumed with a Buy at Needham
01/27/21 Truist
Personalis initiated with a Buy at Truist
01/27/21 Truist
Personalis initiated with a Buy at Truist
01/04/21 BofA
Personalis downgraded to Neutral on valuation at BofA
01/04/21 BofA
Personalis downgraded to Neutral on valuation at BofA
01/04/21 BofA
Personalis downgraded to Neutral from Buy at BofA
01/04/21 BofA
Personalis downgraded to Neutral from Buy at BofA
MEDS Trxade Group
$36.00 /

+16 (+1.00%)

02/26/21 Maxim
Trxade Group initiated with a Buy at Maxim
02/26/21 Maxim
Trxade Group initiated with a Buy at Maxim
12/03/20 National Securities
Trxade Group initiated with a Buy at National Securities
12/03/20 National Securities
Trxade Group initiated with a Buy at National Securities
AMRS Amyris
$33.00 /

+19 (+8.00%)

02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
01/06/21 Cowen
Amyris upgraded to Outperform with $9 price target at Cowen
01/06/21 Cowen
Amyris upgraded to Outperform with $9 price target at Cowen
01/06/21 Cowen
Amyris upgraded to Outperform from Market Perform at Cowen
01/06/21 Cowen
Amyris upgraded to Outperform from Market Perform at Cowen
11/25/20
Fly Intel: Top five analyst initiations
11/25/20
Fly Intel: Top five analyst initiations
PSNL Personalis
$34.00 /

+19 (+1.00%)

MEDS Trxade Group
$36.00 /

+16 (+1.00%)

FATE Fate Therapeutics
$39.00 /

+13 (+8.00%)

  • 29
    Jan
  • 29
    Jan
  • 27
    Jan
  • 27
    Jan
  • 06
    Jan
  • 06
    Jan
  • 12
    Aug
  • 12
    Aug
  • 09
    Jun
  • 09
    Jun
  • 05
    Jun
  • 05
    Jun
PSNL Personalis
$34.00 /

+19 (+1.00%)

MEDS Trxade Group
$36.00 /

+16 (+1.00%)

FATE Fate Therapeutics
$39.00 /

+13 (+8.00%)

AMRS Amyris
$33.00 /

+19 (+8.00%)

AMRS Amyris
$33.00 /

+19 (+8.00%)

Initiation
Calliditas Therapeutics initiated with a Buy at H.C. Wainwright » 06:06
02/26/21
02/26
06:06
02/26/21
06:06
CALT

Calliditas Therapeutics

$28.31 /

-0.48 (-1.67%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edwin Zhang initiated coverage of Calliditas Therapeutics with a Buy rating and $52 price target. Leading in competition, Nefecon could be the first approved drug specific for IgA nephropathy, Zhang tells investors in a research note. If approved, Nefecon could be adopted fast because of its first-mover advantage and high unmet medical need, says the analyst.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$28.31 /

-0.48 (-1.67%)

CALT Calliditas Therapeutics
$28.31 /

-0.48 (-1.67%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 29
    Jan
  • 05
    Jun
Conference/Events
Jefferies biotech analyst to hold an analyst/industry conference call » 10:23
02/05/21
02/05
10:23
02/05/21
10:23
AUPH

Aurinia Pharmaceuticals

$15.46 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$29.99 /

+0.59 (+2.01%)

, RETA

Reata Pharmaceuticals

$112.71 /

+0.45 (+0.40%)

, TVTX

Travere Therapeutics

$31.57 /

+0.05 (+0.16%)

Biotech Analyst Raycroft…

Biotech Analyst Raycroft discusses the various companies focusing on kidney diseases including Aurinia Pharmaceuticals (AUPH), Calliditas Therapeutics (CALT), Reata Pharmaceuticals (RETA) and Travere Therapeutics (TVTX) on an Analyst/Industry conference call to be held on February 5 at 11 am.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$31.57 /

+0.05 (+0.16%)

RETA Reata Pharmaceuticals
$112.71 /

+0.45 (+0.40%)

CALT Calliditas Therapeutics
$29.99 /

+0.59 (+2.01%)

AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

01/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital
01/26/21 Cantor Fitzgerald
Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald
01/25/21 Oppenheimer
Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer
01/25/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
CALT Calliditas Therapeutics
$29.99 /

+0.59 (+2.01%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
RETA Reata Pharmaceuticals
$112.71 /

+0.45 (+0.40%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
TVTX Travere Therapeutics
$31.57 /

+0.05 (+0.16%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$31.57 /

+0.05 (+0.16%)

RETA Reata Pharmaceuticals
$112.71 /

+0.45 (+0.40%)

AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

  • 29
    Jan
  • 02
    Dec
  • 23
    Jul
  • 05
    Jun
AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

RETA Reata Pharmaceuticals
$112.71 /

+0.45 (+0.40%)

AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

TVTX Travere Therapeutics
$31.57 /

+0.05 (+0.16%)

AUPH Aurinia Pharmaceuticals
$15.46 /

+ (+0.00%)

Hot Stocks
Calliditas Therapeutics doses first patient in NefIgArd study » 05:29
02/04/21
02/04
05:29
02/04/21
05:29
CALT

Calliditas Therapeutics

$29.00 /

+0.65 (+2.29%)

Calliditas Therapeutics…

Calliditas Therapeutics announced that the first patient has been dosed in the global open-label extension, or OLE, of the Phase 3 NefIgArd study. OLE offers a nine-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy, or IgAN. This study will evaluate patients who have completed the Phase 3 study NefIgArd, which achieved both its primary and key secondary endpoints in the Part A topline data read out on November 8, 2020. All patients will continue on RAS inhibitor therapy and be treated for nine months with Nefecon in the OLE study. At the end of the treatment period, change in urine protein to creatinine ratio, or UPCR, and change in estimated glomerular filtration rate, or eGFR, will be evaluated. Further, a comparison between treatment naive and those patients who received Nefecon in the Phase 3 NefIgArd study will be made. Three months after completion of treatment, all patients have a scheduled follow up visit.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$29.00 /

+0.65 (+2.29%)

CALT Calliditas Therapeutics
$29.00 /

+0.65 (+2.29%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 29
    Jan
  • 05
    Jun
Over a month ago
Syndicate
Calliditas Therapeutics files to sell 4.5M common shares  17:11
01/26/21
01/26
17:11
01/26/21
17:11
CALT

Calliditas Therapeutics

$31.35 /

-0.68 (-2.12%)

 
ShowHide Related Items >><<
CALT Calliditas Therapeutics
$31.35 /

-0.68 (-2.12%)

CALT Calliditas Therapeutics
$31.35 /

-0.68 (-2.12%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Hot Stocks
Calliditas Therapeutics announces full enrollment of NefIgArd trial » 05:23
01/21/21
01/21
05:23
01/21/21
05:23
CALT

Calliditas Therapeutics

$32.59 /

+0.69 (+2.16%)

Calliditas Therapeutics…

Calliditas Therapeutics announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon versus placebo in patients with primary IgA nephropathy, or IgAN. The NefIgArd trial consists of two parts: Part A and Part B. Part A, which forms the basis for potential regulatory submissions and approvals, provided data on the efficacy and safety of Nefecon. Calliditas read out positive topline data from Part A of the trial on 8 November 2020, announcing that the study met its primary endpoint, reduction in proteinuria, and key secondary endpoint stabilization of eGFR. It also showed that Nefecon was generally well-tolerated. Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. The 360-patient population of the Phase 3 trial includes the further 160 patients enrolled in addition to the 200 patients from Part A.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$32.59 /

+0.69 (+2.16%)

CALT Calliditas Therapeutics
$32.59 /

+0.69 (+2.16%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Conference/Events
Calliditas Therapeutics to host virtual research and development day » 06:55
01/20/21
01/20
06:55
01/20/21
06:55
CALT

Calliditas Therapeutics

$31.90 /

+1.35 (+4.42%)

Research and Development…

Research and Development Virtual Day will be held on January 20 at 7 am. Webcast Link

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Hot Stocks
Calliditas Therapeutics to provide data from Part A of NefIgArd study » 05:17
01/20/21
01/20
05:17
01/20/21
05:17
CALT

Calliditas Therapeutics

$31.90 /

+1.35 (+4.42%)

Calliditas Therapeutics…

Calliditas Therapeutics announced it will provide information on the near-term clinical development plans for setanaxib in primary biliary cholangitis, or PBC, and oncology. It will also present additional data from the Part A of the NefIgArd Phase 3 study, which recently reported positive data. In Q4 of 2020 Calliditas acquired a controlling stake in Genkyotex, which has been developing a first in class platform for NOX inhibition and where the lead compound, setanaxib has been tested in various fibrosis related indications. Following the positive results from the Phase 1 study in January of 2021, which evaluated higher doses of setanaxib in healthy volunteers, Calliditas is planning to initiate a pivotal Phase 2/3 study in PBC, starting in 2H 2021, with final design and protocol details subject to feedback from the FDA. In addition, Calliditas plans to initiate a Phase 2 proof-of-concept study in head and neck cancer this year which will study administration of setanaxib in conjunction with immunotherapy targeting CAFs, or cancer associated fibroblasts. Calliditas will also provide select data from the recently concluded Part A of the Phase 3 study NefIgArd with the lead candidate drug Nefecon, for the treatment of IgA Nephropathy. The data to be presented include overall baseline characteristics, rate of discontinuation of study treatment and rate of discontinuation from the study. It is also confirmed that no adverse clinical effects were seen with regards to weight gain, blood pressure or HbA1c, reflecting a safety profile in keeping with the Phase 2b trial.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Conference/Events
Calliditas Therapeutics to host virtual research and development day » 04:55
01/20/21
01/20
04:55
01/20/21
04:55
CALT

Calliditas Therapeutics

$31.90 /

+1.35 (+4.42%)

Research and Development…

Research and Development Virtual Day will be held on January 20 at 7 am. Webcast Link

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

CALT Calliditas Therapeutics
$31.90 /

+1.35 (+4.42%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Hot Stocks
Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile » 12:28
01/18/21
01/18
12:28
01/18/21
12:28
CALT

Calliditas Therapeutics

$30.55 /

-0.61 (-1.96%)

Genkyotex SA, a…

Genkyotex SA, a subsidiary of Calliditas Therapeutics, announced "positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset." The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified, the company said. The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA, it added. The study assessed the safety and pharmacokinetics of oral setanaxib at selected doses in 46 healthy adult male and female subjects. The trial consisted of a single ascending dose part and a multiple ascending dose part with dosing up to 1600mg/day. Previously, doses of up to 800 mg/day were evaluated in a 24-week Phase 2 trial in PBC patients. In that trial, setanaxib dosed at 800 mg/day achieved reductions in markers of cholestasis, including alkaline phosphatase, and in multiple non-invasive markers of liver fibrogenesis, including liver stiffness and PRO-C3 and C3M. Significant improvement in fatigue was also achieved. All doses tested in that trial were well-tolerated, with no safety signal compared to placebo. Calliditas controls 86.2% of the share capital and total number of votes of Genkyotex.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.